Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

The firm noted Moderna's reduced 2024 sales forecast of $3.0–$3.1 billion, down from $3.0–$3.5 billion, driven by declines in ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...

In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

Cook your food thoroughly (especially seafood and shellfish) to at least 145 degrees Fahrenheit. Clean and sanitize surfaces ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...